Tuesday, August 19, 2025
'Ukraine Telecom Kyivstar Extends Gains as Trump Pushes for Peace'
Shares of Kyivstar Group Ltd., Ukraine’s largest mobile operator, jump as much as 22% in their third trading session since the company went public in the US by merging with a blank-check firm.
PainReform’s DeepSolar unit joins NVIDIA Connect Program
PainReform Ltd. (NASDAQ:PRFX), a micro-cap company with a market value of $2.7 million, announced Tuesday that its solar energy business unit, DeepSolar, has been accepted into the NVIDIA Connect Program, a development track for companies building AI-based solutions.
The program will provide DeepSolar with access to NVIDIA’s AI frameworks, development tools, and engineering support to advance DeepSolar Predict, the company’s solar forecasting solution for photovoltaic systems.
According to the company’s press release, DeepSolar Predict aims to improve weather forecast accuracy by up to 50%, potentially helping solar asset owners reduce imbalance penalties, maximize revenue through better energy sale timing, and provide more stable supply to the grid.
"By combining NVIDIA’s AI capabilities with DeepSolar’s domain expertise, we believe that DeepSolar Predict has the potential to redefine how photovoltaic energy is forecasted and optimized," said Ehud Geller, Chairman and Interim CEO of PainReform.
The company stated that its existing software platform has demonstrated the ability to enhance energy production and reduce operational and maintenance costs by up to 30%. Initial engagement with PV developers and utility-scale operators is underway to evaluate the new forecasting solution in real-world environments.
The NVIDIA Connect Program provides participants with early access to software development kits, preferred hardware/software pricing, and technical co-development opportunities.
PainReform operates a dual business model, developing both pharmaceutical products for post-surgical pain relief and AI-driven energy optimization technologies through its DeepSolar platform.
In other recent news, PainReform Ltd. has completed its strategic investment in LayerBio, Inc., acquiring a majority equity stake in the Boston-based biotechnology company. This acquisition will allow PainReform to advance clinical trials for OcuRing-K, LayerBio’s lead investigational product. OcuRing-K is designed to control pain and inflammation following cataract surgery. The investment agreement includes a commitment of up to $3 million, contingent on achieving specific development milestones. An initial investment of $600,000 has already been made, with the remaining funds to be provided in tranches as LayerBio reaches its developmental goals. This strategic move positions PainReform to expand into the ophthalmology sector. The company will also secure a majority position on LayerBio’s board as part of the agreement. These developments represent PainReform’s efforts to broaden its scope in the biotechnology field.
Subscribe to:
Posts (Atom)